Novavax, Inc. (NVAX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Novavax, Inc. (NVAX) is up 33.9% since the beginning of the year. At $9 per share, NVAX is trading 24.8% below its 52-week high of $12. Investors who bought $1,000 worth of NVAX shares 5 years ago would now be looking at an investment worth $47.

Novavax, Inc. (NVAX) has returned 33.93% so far this year and 40.41% over the past 12 months. Over the last ten years, NVAX has returned -23.62% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.

Based on dividend-adjusted daily data since Dec 13, 1995, NVAX's average daily return is +0.15%, while the average monthly return is +2.80%. At this rate, an investment would double in approximately 2.1 years.

Historically, 47% of months were positive and 53% were negative. The best month was May 2024 with a return of +247.1%, while the worst month was Feb 2019 at -69.9%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 10 months.

On a daily basis, NVAX closed higher 44% of trading days. The best single day was May 10, 2024 with a return of +98.7%, while the worst single day was Sep 16, 2016 at -84.5%.

Novavax, Inc. has an annualized alpha of 29.82%, beta of 1.24, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since December 13, 1995.

• This stock participated in 169.16% of S&P 500 Index downside but only 116.41% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NVAX ranks 63 for risk / return — better than 63% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Novavax, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Novavax, Inc. was 98.82%, occurring on Feb 5, 2024. The portfolio has not yet recovered.

The current Novavax, Inc. drawdown is 97.19%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Novavax, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Novavax, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.